Changes in plasma levels of atrial natriuretic peptide, endothelin-1 and von Willebrand factor among newborns with persistent pulmonary hypertension

Chinese Journal of Contemporary Pediatrics

Volumn 15, Issue 9, 2013, Pages 718-722

  Yao, Ai Min ^a   Hao, Ya Ping ^a   Zhang, Jie ^a   Sun, Xue Jiang ^a   Wang, Hong Ying ^a   Li, Bin ^a   Li, Jian Ling ^a  

^a Maternal and Child Care Service Centre   (China)

Author keywords

Atrial natriuretic peptide; Endothelin 1; Newborn; Persistent pulmonary hypertension; Von Willebrand factor

Indexed keywords

ATRIAL NATRIURETIC FACTOR; ENDOTHELIN 1; VON WILLEBRAND FACTOR;

ARTICLE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; HYPOXEMIA; MAJOR CLINICAL STUDY; NEWBORN; PERSISTENT PULMONARY HYPERTENSION; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

ATRIAL NATRIURETIC FACTOR; ENDOTHELIN-1; HUMANS; INFANT, NEWBORN; PERSISTENT FETAL CIRCULATION SYNDROME; PULMONARY ARTERY; SYSTOLE; VON WILLEBRAND FACTOR;

EID: 84888219260     PISSN: 10088830     EISSN: None     Source Type: Journal    
DOI: 10.7499/j.issn.1008-8830.2013.09.003     Document Type: Article

References (23)

1. Helset E, Kjaeve J, Bjertnaes L. Acute alveolar hypoxia increases endothelin-1 release but decreases release of calcitonin generelated peptide in isolated perfused rat lungs[J]. Sand J Clin Lab Invest, 1995, 55: 369-376.
2. Abman SH. Recent advances in the pathogenesis and treatment of persistent pul-monary hypertension of the newborn [ J ] Neonatology, 2007, 91(4): 283-290.
3. Kangawa K, Matsuo H. Purification and complete aminoaeid Sequence of alpha-human atrial natriuretic polypeptide(alpha-hANP)[J]. Biochem Biophys Res Commun, 1984, 118(1): 131.
4. Vaz Perez A, Doehner W, Von Haehling S. The relationship between tumor necrosis factor- α, brain natriuretic peptide and atrial natriuretic peptide in patients with chronic heart failure[J]. Int J Cardiol, 2010, 141 (1) : 39-43.
5. Gerczuk PZ, Kloner RA. An update on cardioprotection a review of the latest adjunctive therapies to limit myocardial infarcction size in clinical trials[J]. J Am Coll Cardiol, 2012, 59 (11) : 970-978.
6. Koga H, Hagiwara S, Kusaka J, Matsumoto S, Nishida T, Yokoi I, et al. Human atrial natriuretic peptide attenuates renal ischemia-reperfusion injury[J]. J Surg Res, 2012, 173(2): 348-353.
7. Krishnan U. Management of Pulmonary Arterial Hypertension in the Neonatal Unit[J]. Cardiol Rev, 2010, 18(2): 73-75.
8. Giaid A, Yanagisawa M, Langleben D. Expression of endothelin-1 in the lungs of patients with pulmona hypertension[J]. N Engl J Med, 1993, 328(24): 1732-1739.
9. Blann AD, T abemer DA. A reliable marker ofendothelial cell dysfunction: Does it exist?[J]. Br JHaematol, 1995, 90(2): 244-248.
10. Lopes AA, Barreto AC, Maeda NY, Cicero C, Soares RPS, Bydlowski SP. et al. Plasma von Willebrand factor as a predictor of survival in pulmonary arterial hypertension associated with congenital heart disease [J]. Brazil J Med Biol Res, 2011, 44(12): 1269-1275.
11. Alian Z, Hashemipour M, Dehkordi EH, Hovsepian S, Amini M, Moadab MH, et al. The effects of folic acid on markers of endothelial function in patients with type1 diabetes mellitus[J]. MED ARH, 2012, 66(2): 12-15.
12. Vischer UM. von Willebrand factor, endothelial dysfunction, and cardiovascular disease[J]. Thromb Haemost, 2006, 4(11): 86-93.